— Aethlon Medical (NASDAQ: AEMD) reported third quarter 2020 net loss attributable to company of $820,000 or $0.28 per share vs. a loss of $2.1 million $1.67 per share in the prior-year quarter.
— Government contract revenue was $413,458 for the three months ended December 31, 2019.
— Operating expenses were $1.29 million compared to $1.96 million in the three months ended December 31, 2018.
— Aethlon announced that SEC had temporarily suspended trading of the company stock for a period of ten days.
— Aethlon clarified that its proprietary blood filtration cartridge Hemopurifier, which is in the development stage, would not be an initial front line treatment for the 2019-nCoV virus.
Most Popular
NKE Earnings: Nike reports lower sales for Q3 2025
NIKE, Inc. (NYSE: NKE) has reported a decline in earnings for the third quarter of 2025, hurt by a slowdown in sales across all major markets and operating segments. The
NIO Infographic: A snapshot of Nio’s Q4 2024 earnings report
China-based electric car maker NIO Inc. (NYSE: NIO) on Friday reported a net loss for the fourth quarter of 2024. Revenues increased by double-digits during the three months. Total revenues
Infographic: How FedEx (FDX) performed in Q3 2025
FedEx Corp. (NYSE: FDX) reported revenue of $22.2 billion for the third quarter of 2025, up 2% compared to the same quarter a year ago. GAAP net income was $909
